Archeus Technologies has announced the dosing of its first patient in a Phase 1 clinical trial for ARC-706, a radiopharmaceutical therapy aimed at treating metastatic cancer. This trial will also utilize ARC-166, a companion diagnostic, to guide treatment decisions. The primary goal is to evaluate the safety, biodistribution, and pharmacokinetics of ARC-706, which incorporates yttrium-90 for therapeutic purposes and yttrium-86 for imaging. The study is particularly focused on patients undergoing immune checkpoint inhibition (ICI) therapies, aiming to enhance their treatment response despite disease progression. Grace Blitzer, M.D., a principal investigator, emphasized the potential of this approach to provide clinical benefits without disrupting ongoing immune treatments. Preclinical data indicates that ARC-706 can selectively target tumors and improve the efficacy of ICI therapies. This trial reflects Archeus's commitment to advancing innovative radiopharmaceutical strategies for challenging cancers, supported by its collaboration with the University of Wisconsin–Madison, a leader in radiopharmaceutical research.